II期临床-话题@MedSci

#II期临床#

478篇内容 | 2505人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524987, encodeId=6493152498eae, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功, objectType=article, longId=221809, objectId=99492218096b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99492218096b, replyNumber=0, likeNumber=68, createdTime=2021-12-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99492218096b, moduleTitle=NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99492218096b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524986, encodeId=ede71524986b9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, objectType=article, longId=221687, objectId=bc7922168e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7922168e72, replyNumber=0, likeNumber=89, createdTime=2021-12-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7922168e72, moduleTitle=NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7922168e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524985, encodeId=fbee15249854d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, objectType=article, longId=221311, objectId=7491221311ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7491221311ab, replyNumber=0, likeNumber=54, createdTime=2021-12-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7491221311ab, moduleTitle=Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7491221311ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524984, encodeId=f33215249846a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, objectType=article, longId=221301, objectId=e3df221301c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3df221301c8, replyNumber=0, likeNumber=78, createdTime=2021-12-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3df221301c8, moduleTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3df221301c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524983, encodeId=d7e51524983b1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, objectType=article, longId=221179, objectId=74cf2211e969, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cf2211e969, replyNumber=0, likeNumber=68, createdTime=2021-11-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cf2211e969, moduleTitle=Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cf2211e969)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524982, encodeId=60691524982f3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS, objectType=article, longId=220829, objectId=c5ee220829b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5ee220829b8, replyNumber=0, likeNumber=79, createdTime=2021-11-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5ee220829b8, moduleTitle=Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5ee220829b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524981, encodeId=a7d6152498171, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=安可达III期临床研究设计及数据解读, objectType=article, longId=220755, objectId=9535220e55a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9535220e55a8, replyNumber=0, likeNumber=44, createdTime=2021-11-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9535220e55a8, moduleTitle=安可达III期临床研究设计及数据解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9535220e55a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524980, encodeId=0b7715249805c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=43, createdTime=2021-11-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524979, encodeId=cfbb15249e937, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, objectType=article, longId=219794, objectId=be3b219e94bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be3b219e94bc, replyNumber=0, likeNumber=73, createdTime=2021-11-06, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be3b219e94bc, moduleTitle=乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be3b219e94bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524978, encodeId=310c15249e8e9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：白细胞介素-23 Risankizumab治疗严重哮喘II期临床失败, objectType=article, longId=219618, objectId=26792196183f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26792196183f, replyNumber=0, likeNumber=75, createdTime=2021-11-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26792196183f, moduleTitle=NEJM：白细胞介素-23 Risankizumab治疗严重哮喘II期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26792196183f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524977, encodeId=745115249e7d2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, objectType=article, longId=219261, objectId=3c982192618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c982192618a, replyNumber=0, likeNumber=78, createdTime=2021-10-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c982192618a, moduleTitle=“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c982192618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524976, encodeId=6f6515249e6e9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2021年10月23日简报：本轮本土疫情波及10省市，因为冷冻食品和动物可传播，源头追踪变得困难和复杂；欧亚多国疫情猛烈反弹，新冠新变种病毒AY 4.2.快速扩散，新一波疫情迹象出现；罗氏新冠药物合作方宣布新冠口服II期临床研究失败, objectType=article, longId=219098, objectId=f3742190989b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3742190989b, replyNumber=0, likeNumber=65, createdTime=2021-10-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3742190989b, moduleTitle=2021年10月23日简报：本轮本土疫情波及10省市，因为冷冻食品和动物可传播，源头追踪变得困难和复杂；欧亚多国疫情猛烈反弹，新冠新变种病毒AY 4.2.快速扩散，新一波疫情迹象出现；罗氏新冠药物合作方宣布新冠口服II期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3742190989b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524975, encodeId=3ccc15249e598, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=42, createdTime=2021-10-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524974, encodeId=a2eb15249e49c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, objectType=article, longId=218737, objectId=eb23218e37f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb23218e37f3, replyNumber=0, likeNumber=58, createdTime=2021-10-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb23218e37f3, moduleTitle=靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb23218e37f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524973, encodeId=4b9715249e3eb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, objectType=article, longId=218304, objectId=0e0c218304c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e0c218304c9, replyNumber=0, likeNumber=71, createdTime=2021-10-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e0c218304c9, moduleTitle=糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e0c218304c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524972, encodeId=eb7d15249e2b3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , objectType=article, longId=218140, objectId=973121814015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=973121814015, replyNumber=0, likeNumber=82, createdTime=2021-10-07, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=973121814015, moduleTitle=Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973121814015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524971, encodeId=d44315249e16b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, objectType=article, longId=218128, objectId=301e21812880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301e21812880, replyNumber=0, likeNumber=59, createdTime=2021-10-06, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301e21812880, moduleTitle=Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=301e21812880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524970, encodeId=954215249e0a8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, objectType=article, longId=217765, objectId=135021e76506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=135021e76506, replyNumber=0, likeNumber=65, createdTime=2021-09-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=135021e76506, moduleTitle=巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=135021e76506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524969, encodeId=61cb1524969f2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, objectType=article, longId=217668, objectId=1fca21e668fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fca21e668fc, replyNumber=0, likeNumber=65, createdTime=2021-09-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fca21e668fc, moduleTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fca21e668fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524968, encodeId=c8fb1524968df, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, objectType=article, longId=217525, objectId=c79c21e52563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c79c21e52563, replyNumber=0, likeNumber=70, createdTime=2021-09-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c79c21e52563, moduleTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c79c21e52563)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：Tapinarof乳膏局部治疗银屑病III期临床获得成功

2021-12-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：新冠抗体鸡尾酒疗法REGEN-COV III期临床研究结果喜人

2021-12-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Oncologist:化疗难治性食管鳞状细胞癌患者使用apatinib（阿帕替尼）的疗效和安全性：II期临床研究

2021-12-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究

2021-12-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Front Oncol：Lenvatinib（仑伐替尼）联合PD-1抑制剂一线治疗初始不可切除胆道癌(BTC)的疗效和安全性：单臂、开放标签II期临床研究

2021-11-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS

2021-11-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

安可达III期临床研究设计及数据解读

2021-11-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2021-11-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

乐复能治疗重症新冠肺炎III期临床试验数据公布，降低重症病人的呼吸衰竭和死亡率58.3%

2021-11-06

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：白细胞介素-23 Risankizumab治疗严重哮喘II期临床失败

2021-11-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

“吹口气测新冠”成为可能，mRNA疫苗加强针III期临床试验保护效力为95.6%丨新冠研究一周进展

2021-10-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2021年10月23日简报：本轮本土疫情波及10省市，因为冷冻食品和动物可传播，源头追踪变得困难和复杂；欧亚多国疫情猛烈反弹，新冠新变种病毒AY 4.2.快速扩散，新一波疫情迹象出现；罗氏新冠药物合作方宣布新冠口服II期临床研究失败

2021-10-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2021-10-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

靶向IL-4R单克隆抗体 (AK120) 治疗特应性皮炎和哮喘，中国II期临床试验已经启动

2021-10-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

糖尿病创新药iGlarLixi中国III期临床试验达到主要有效性终点

2021-10-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Front Oncol：ER+/HER2-且淋巴结阳性的绝经前乳腺癌患者，新辅助化疗（NCT）对比新辅助内分泌治疗（NET）的疗效：III期临床研究NEST

2021-10-07

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Proxalutamide用于治疗美国住院COVID-19患者的III期临床试验，首次对患者给药

2021-10-06

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

巴西ANVISA批准Proxalutamide用于治疗住院COVID-19患者的III期临床试验

2021-09-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床

2021-09-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索

2021-09-25

科室
- - 订阅+
  - 更多科室
工具
服务